Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylphenidate sustained release - DURECT Corporation

Next Previous
Drug Profile

Methylphenidate sustained release - DURECT Corporation

Alternative Names: Methydur; Methydur sustained release capsules; ORADUR-ADHD; ORADUR-Methylphenidate; ORADUR®-Methylphenidate ER

Latest Information Update: 26 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DURECT Corporation
  • Developer DURECT Corporation; Orient Pharma
  • Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Attention-deficit hyperactivity disorder; Attention-deficit hyperactivity disorder

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 30 Sep 2020 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children) in Taiwan (PO)
  • 18 Sep 2018 Orient Pharma intends to launch ORADUR-methylphenidate extended-release capsule for Attention deficit hyperactivity disorder in Taiwan in 2019
  • 18 Sep 2018 Methylphenidate sustained release - DURECT Corporation is available for licensing in Asia, Pacific Rim countries (excluding Europe, Japan, North America) as of 18 Sep 2018. http://www.oppharma.com/index.php/eng/index
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top